SLC38A7 and cancer: Preclinically, inhibitors of biosynthetic enzymes, such as the SBP enzyme PHGDH are under development for a wide array of cancers (116, 132, 133), and drugs to target amino acid transporters, such as LAT1 (SLC7A5), are also being explored (146, 147).